ArsenalBio to Funnel $220M From Series B Into CAR T Therapy Advancement Efforts

San Francisco, California-based programmable cell therapy company Arsenal Biosciences, known for developing innovative CAR T therapies for solid tumors, has wrapped up a lucrative Series B financing round totaling $220 million. The oversubscribed round featured contributions from a batch of new investors including Softbank Vision Fund 2, Bristol-Myers...